🕒 Last update: loading…16/11/2026

Stock Charles River Laboratories International, Inc. CRL

Charles River Laboratories International, Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met. Data as of 01/11/2026.

  • ✅ Price trend passed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): the price has been multiplied by at least 1.5.

Price change 2018 → 2019: 34.97%

Price change 2019 → 2020: 63.56%

Price change 2020 → 2021: 50.80%

Price change 2021 → 2022: -42.17%

Price change 2022 → 2023: 8.49%

Price change 2023 → 2024: -21.91%

Price change 2024 → 2025: 8.06%

Price change 2025 → 2026: 74.22%

Price change 2026 (year to date): 71.69%

Financial growth

Revenue CAGR (8 years): 8.52%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 0.97

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 35.17

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 7.60% from the high over 6 months.

Insufficient correction (< 10.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Charles River Laboratories International, Inc.34.10.97+8.8 %🔒
Ipsen S.A.25.60.20+7.9 %–
Tempus AI, Inc.–2.70+65.4 %–
bioMérieux S.A.23.50.11+7.6 %★ 4/5
BioNTech SE–0.01+60.8 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Charles River Laboratories International, Inc. over the latest fiscal years.

Revenue
4.0 bn USD
fiscal year 2025
Net income
-144 m USD
fiscal year 2025
Net margin
-3.6 %
fiscal year 2025
Average annual growth
+6.5 %
Revenue growth over 5 years
Average annual growth
+11.4 %
Revenue growth over 10 years
Market cap
16.2 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
20202.9 bn364 m12.5 %n/a
20213.5 bn391 m11.0 %+21.1 %
20224.0 bn486 m12.2 %+12.3 %
20234.1 bn475 m11.5 %+3.9 %
20244.0 bn10.3 m0.2 %-1.9 %
20254.0 bn-144 m-3.6 %-0.9 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Charles River Laboratories International, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
3.28
safe zone (above 2.99)
Piotroski Score
8 / 9
7 to 9: solid accounts
DCF Value
84.38 USD
DCF below share price · share price 339.88 USD, gap -75.2 %
Net Debt / EBITDA
9.03 x
high debt
Fiscal year20212022202320242025
Cash and investments246 m234 m277 m195 m214 m
Total Debt3.2 bn3.1 bn3.1 bn2.7 bn3.1 bn
Net Debt3.0 bn2.9 bn2.8 bn2.5 bn2.9 bn
Equity2.5 bn3.0 bn3.6 bn3.5 bn3.2 bn
Total assets7.0 bn7.6 bn8.2 bn7.5 bn7.1 bn
Operating cash flow761 m620 m684 m735 m738 m
Investments (capex)229 m325 m319 m233 m219 m
Free cash-flow532 m295 m365 m502 m518 m
Share buybacks40.7 m38.7 m24.2 m119 m361 m
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)334.13 x
Price / book value5.05 x
Return on Equity (ROE)1.3 %
Return on Invested Capital (ROIC)-3.8 %
Net margin1.0 %
Debt / equity0.88 x
Current ratio1.41 x
Interest coverage5.14 x
Free cash-flow yield2.5 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Valuation and competitors

Charles River Laboratories International, Inc. compared with its sector on the same exchange and with its main competitors.

Company P/E
34.1
23.2 % above the sector
Sector median P/E
27.7
healthcare, NYSE
Sector over 10 years
22.3
10-year median, range 18.4 to 44.9

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Charles River Laboratories International, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
37 analysts
Average price target
313.67 USD
from 219.00 USD to 388.00 USD, 41 targets over 12 months
Gap with the share price
-7.1 %
price 337.52 USD on 06/11/2026

Breakdown of ratings

strong buy 1buy 27hold 9sell 0strong sell 0

Analysts' average target 313.67 USD, DCF value 84.38 USD, share price 337.52 USD.

Average target over the last 3 months: 333.83 USD (12 targets).

Analyst forecasts

Fiscal yearRevenueNet incomeExpected EPS (range)P/E on this EPSAnalysts
20263.9 bn563 m11.38 (11.20 / 11.51)29.710
20274.0 bn619 m12.80 (12.10 / 13.06)26.410
20284.2 bn697 m14.33 (10.17 / 17.84)23.66

Amounts in USD, the reporting currency.

Track record against expectations: reported EPS above consensus 12 times over the last 12 releases.

Rating changes (12 months)

DateFirmBeforeAfter
05/11/2026UBSBuyBuy
05/11/2026RBC CapitalOutperformOutperform
05/11/2026BarclaysOverweightOverweight
05/11/2026Evercore ISI GroupOutperformOutperform
13/10/2026Morgan StanleyOverweightOverweight

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Charles River Laboratories International, Inc.

Large funds tracked
26
hold the stock as of 2026Q2
Executives (insiders)
1 / 20
1 purchases, 20 sales in 130 days

Indices: S&P 500 (since 14/05/2021).

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
Vanguard Group5.9 m1.2 bn0.0 %+0.8 %2025Q4
Fidelity4.2 m962 m0.0 %+22.7 %2026Q2
BlackRock3.8 m861 m0.0 %-1.6 %2026Q2
State Street3.7 m846 m0.0 %+99.0 %2026Q2
Invesco3.0 m677 m0.1 %+24.5 %2026Q2
Citadel Advisors2.4 m541 m0.2 %+96.9 %2026Q2
Harris Associates2.2 m508 m0.7 %+4.1 %2026Q2
Ariel Investments1.5 m342 m3.4 %+4.3 %2026Q2

Latest insider transactions

DatePersonSideAmount
22/10/2026Foster James Csale8.4 m USD
21/10/2026Parisotto Shannon Msale742,548 USD
05/10/2026Parisotto Shannon Msale302,580 USD
30/09/2026Coleman Glennpurchase2,974 USD
25/08/2026Foster James Csale10.1 m USD
19/08/2026Parisotto Shannon Msale599,711 USD

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 16/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
NYSE
IPO: 23/06/2000
ISIN code
US1598641074
Workforce
18,700
full-time employees
Chief executive
James C. Foster
Next earnings
17/02/2027

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Charles River Laboratories International, Inc.

What is the Charles River Laboratories International, Inc. share price?

Latest recorded price: 337.97 USD on 13/11/2026, for a market cap of 16.2 bn USD.

What is the revenue of Charles River Laboratories International, Inc.?

4.0 bn USD for fiscal year 2025, with net income of -144 m USD (net margin -3.6 %).

When does Charles River Laboratories International, Inc. report its next earnings?

The next release is expected on 17/02/2027. EPS expected by analysts: 3.32.

What do analysts say about Charles River Laboratories International, Inc.?

Out of 37 analysts: 28 buy or strong buy, 9 hold, 0 sell or strong sell. Average price target: 313.67 USD, i.e. -7.1 % from the share price.

What is the P/E ratio of Charles River Laboratories International, Inc.?

Trailing 12-month P/E of 34.1, against 27.7 for the sector median on the same exchange (10-year median: 22.3).

Is Charles River Laboratories International, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US1598641074).

How many employees does Charles River Laboratories International, Inc. have?

18,700 full-time employees according to the latest published profile.

Who runs Charles River Laboratories International, Inc.?

James C. Foster is the company's chief executive.

Which large funds own Charles River Laboratories International, Inc.?

As of 2026Q2, among the large funds tracked: Vanguard Group, Fidelity, BlackRock, State Street, Invesco.

07

Similar stocks